Filing Flows › Integrated Biopharma (INBP) › Q1 FY26
Integrated Biopharma (INBP) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Nov 10, 2025
Integrated Biopharma (INBP) reported revenue of $12.7M for the first quarter fiscal 2026 (Q1 FY26), -7% from a year earlier and -10% from the quarter before. Operating margin was 1.3%, net earnings $123K (1.0% of revenue).
Integrated Biopharma, Q1 FY26: revenue $12.7M (-7% year over year), operating margin 1.3%, net earnings $123K, operating cash flow $1.3M. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.7M | -10% | -7% |
| Gross profit | $1.0M | -31% | -26% |
| Operating profit | $163K | -72% | -67% |
| Net earnings | $123K | — | -53% |
| Operating cash flow | $1.3M | +120% | +98% |
| Free cash flow | $1.1M | +88% | +88% |
What changed
Revenue was $12.7M in Q1 FY26, down 7% year over year and down 10% from the previous quarter. Contract Manufacturing was the largest line at 96% of revenue. Contract Manufacturing lost $806K year over year (down 6%), 87% of the total change.
Gross margin was 8.0%, down 2.0 points from a year earlier. Operating profit was $163K, a 1.3% margin (down 2.3 points year over year). Operating expenses fell 3% while revenue fell 7%. Net earnings were $123K, down 53% year over year. The effective tax rate was 37.2%.
Operating cash flow was $1.3M (up 98% year over year), 1058% of net earnings. Non-cash charges added back $77K of depreciation and $49K of share-based compensation. Working capital and other items added $1.1M. Capital expenditures of $173K left free cash flow of $1.1M.
Questions
What was Integrated Biopharma's revenue in the first quarter fiscal 2026?
Integrated Biopharma (INBP) reported revenue of $12.7M for the first quarter fiscal 2026 (Q1 FY26), -7% from a year earlier and -10% from the quarter before.
Was Integrated Biopharma profitable in the first quarter fiscal 2026?
Operating profit was $163K (1.3% of revenue) and net earnings $123K.